NASDAQ:MIRA MIRA Pharmaceuticals (MIRA) Stock Price, News & Analysis $1.26 -0.14 (-9.96%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About MIRA Pharmaceuticals Stock (NASDAQ:MIRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MIRA Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.13▼$1.4150-Day Range$1.05▼$2.2052-Week Range$0.51▼$5.04Volume682,473 shsAverage Volume3.43 million shsMarket Capitalization$20.95 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingBuy Company OverviewMIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.Read More… Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. MIRA Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks49th Percentile Overall ScoreMIRA MarketRank™: MIRA Pharmaceuticals scored higher than 49% of companies evaluated by MarketBeat, and ranked 570th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingMIRA Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMIRA Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about MIRA Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MIRA Pharmaceuticals are expected to grow in the coming year, from ($0.60) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MIRA Pharmaceuticals is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MIRA Pharmaceuticals is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMIRA Pharmaceuticals has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MIRA Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.65% of the float of MIRA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMIRA Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MIRA Pharmaceuticals has recently increased by 267.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMIRA Pharmaceuticals does not currently pay a dividend.Dividend GrowthMIRA Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.65% of the float of MIRA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMIRA Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MIRA Pharmaceuticals has recently increased by 267.78%, indicating that investor sentiment is decreasing significantly. News and Social Media3.7 / 5News SentimentN/A News SentimentMIRA Pharmaceuticals has a news sentiment score of 1.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.Search Interest21 people have searched for MIRA on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows5 people have added MIRA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MIRA Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.65% of the stock of MIRA Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 35.16% of the stock of MIRA Pharmaceuticals is held by institutions.Read more about MIRA Pharmaceuticals' insider trading history. Receive MIRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MIRA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MIRA Stock News HeadlinesMIRA Continues Solid Financial ManagementNovember 13, 2024 | finance.yahoo.comMira Pharmaceuticals announces preclinical data on Ketamir-2October 29, 2024 | markets.businessinsider.comTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.November 21, 2024 | Angel Publishing (Ad)MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management TrialsOctober 29, 2024 | finance.yahoo.comMIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic PainOctober 28, 2024 | finance.yahoo.comMIRA says Ketamir-2 outperforms FDA-approved neuropathic pain treatmentsOctober 23, 2024 | markets.businessinsider.comMIRA Continues to Post Outstanding Test ResultsOctober 21, 2024 | msn.comMira Pharmaceuticals (NASDAQ:MIRA) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comSee More Headlines MIRA Stock Analysis - Frequently Asked Questions How have MIRA shares performed this year? MIRA Pharmaceuticals' stock was trading at $1.05 at the start of the year. Since then, MIRA shares have increased by 20.5% and is now trading at $1.2650. View the best growth stocks for 2024 here. How were MIRA Pharmaceuticals' earnings last quarter? MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) posted its earnings results on Tuesday, November, 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04. When did MIRA Pharmaceuticals IPO? MIRA Pharmaceuticals (MIRA) raised $9 million in an initial public offering (IPO) on Thursday, August 3rd 2023. The company issued 1,275,000 shares at a price of $7.00 per share. Who are MIRA Pharmaceuticals' major shareholders? Top institutional investors of MIRA Pharmaceuticals include Cross Staff Investments Inc (2.48%) and Suncoast Equity Management (0.61%). Insiders that own company stock include George Cappy, Brian Patrick Mcnulty and Erez Aminov. View institutional ownership trends. How do I buy shares of MIRA Pharmaceuticals? Shares of MIRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of MIRA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that MIRA Pharmaceuticals investors own include Plug Power (PLUG), Workhorse Group (WKHS), FuelCell Energy (FCEL), Fortress Biotech (FBIO), Ovid Therapeutics (OVID), Alamos Gold (AGI) and GeoVax Labs (GOVX). Company Calendar Last Earnings11/12/2024Today11/20/2024Fiscal Year End12/31/2024Next Earnings (Estimated)4/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MIRA Previous SymbolNASDAQ:MIRA CUSIPN/A CIK1904286 Webmirapharmaceuticals.com Phone737-289-0835FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$17.00 Low Stock Price Target$11.00 Potential Upside/Downside+1,006.7%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-337.44% Return on Assets-280.58% Debt Debt-to-Equity RatioN/A Current Ratio6.11 Quick Ratio6.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.30 per share Price / Book4.22Miscellaneous Outstanding Shares16,560,000Free Float15,460,000Market Cap$20.95 million OptionableNot Optionable Beta3.09 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:MIRA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MIRA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MIRA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.